Atypical methotrexate dermatitis and vasculitis in a patient with ankylosing spondylitis.
Reports of histologically proven low-dose methotrexate (MTX)-induced vasculitis are uncommon and mostly found for patients with rheumatoid arthritis. Herein we present a patient with ankylosing spondylitis who developed large atypical erythematopurpuric cutaneous lesions after the second oral dose of 7.5 mg MTX therapy. The histological findings of a cutaneous lesion were consistent with vasculitis. The skin lesions regressed significantly after the discontinuation of MTX therapy. As the clinical picture of the patient's rheumatological condition became progressively severe, prednisolone therapy was initiated 8 days later and the skin rash resolved completely in a couple of weeks.
Borman
P
P
Department of Physical Medicine and Rehabilitation, Numune Education and Research Hospital, Samanpazari, Ankara, Turkey. pinarb@ato.org.tr
Bodur
H
H
Güleç
A T
AT
Uçan
H
H
Seçkin
U
U
Mocan
G
G
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003872:Dermatitis / Q000209:etiology*; D005260:Female; D006801:Humans; D008727:Methotrexate / Q000009:adverse effects* / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D014657:Vasculitis / Q000139:chemically induced*
D000893:Anti-Inflammatory Agents; D018501:Antirheumatic Agents; D011239:Prednisolone; D008727:Methotrexate